After Sanofi leadership telegraphed an upsized appetite for business development last month, signals have emerged that the French Pharma may be eyeing a deal to acquire Insmed, the developer of new respiratory medicine Brinsupri, which appears well on its way to cementing its blockbuster status this year.
Sanofi is now speaking with advisers as it appraises a potential acquisition of Insmed, Bloomberg first reported Thursday, citing confidential sources close to the matter. Under recently arrived CEO Belén Garijo, M.D., Ph.D., Sanofi has been assessing the levers it can pull as it looks to mount a defense against a looming Dupixent patent cliff and a series of recent pipeline misfires.
But the talks over a possible Insmed buyout are ongoing and it could still be weeks before a deal emerges, if at all, Bloomberg’s sources stressed. Sanofi could eventually forego making an offer, and other bidders may step up to the plate too, they added.
Spokespeople at both Sanofi and Insmed declined to comment on the report when reached by Fierce.
Speaking to journalists during the company’s third-quarter earnings call in October, financial chief François-Xavier Roger told Fierce that Sanofi will pursue external growth opportunities as it attempts to straighten out its near-term trajectory. He signaled “an increased interest in late-stage and commercial medicines in our core disease areas, complemented with disciplined built-in acquisitions of early-stage projects.”
Adding that those business development and M&A opportunities could carry a higher price tag than Sanofi had originally planned for, Roger said that the company aimed to share more on its priorities by year-end, while cautioning against the likelihood of a major transaction over the next couple months.
Beyond near-term potential revenue drivers, which an Insmed deal could deliver—and in familiar respiratory territory for Sanofi—the company is also appraising “what we call white spaces or moonshots with unmet medical needs,” Roger said last month in reference to his company’s broader external priorities.
From its protective antibody for RSV, Beyfortus, to flu shots and COVID vaccines, plus its immunology stalwart Dupixent, Sanofi would be well positioned to leverage its existing respiratory expertise around Brinsupri.
Approved last summer, Insmed’s Brinsupri became the first DPP1 inhibitor to hit the U.S. market after clearance from the FDA to treat non-cystic fibrosis bronchiectasis (NCFBE) in adults and kids ages 12 years and older. At the time of approval, analysts at Mizuho predicted Brinsupri could eventually lock up $6.6 billion in peak sales in that indication alone.
NCFBE causes the walls of the body’s airways to widen and thicken from inflammation and infection. This primarily leads to frequent coughing as the body tries to clear infected mucus.
Insmed itself has pinned high hopes on Brinsupri’s sales trajectory, with CEO Will Lewis calling his company’s 2026 sales forecast of $1 billion “audacious” when it was first revealed earlier this year. At the time, Lewis noted that the Brinsupri launch had “surpassed even our most ambitious expectations,” which he said were informed by a “basket of historically strong respiratory launches.”
Insmed reported a little over $917 million in global Brinsupri sales over the first nine months of 2026. The company now expects total sales of the drug to hit $1.35 billion to $1.4 billion this year.
Still, the road for Brinsupri hasn’t been entirely without potholes.
Back in March, Insmed called it quits on a program studying the drug in adults with moderate to severe hidradenitis suppurativa (HS) after a phase 2b trial failed to hit its primary or secondary endpoints. And a few months before that in December, Insmed ended its Brinsupri efforts in chronic rhinosinusitis without nasal polyps (CRSsNP).
Insmed also boasts another commercial product in Arikayce, a nebulizer-based treatment for mycobacterium avium complex (MAC) lung disease that was approved in 2018.
Insmed’s stock price was up more than 18% as of early afternoon Thursday.
With a current potential value now exceeding $30 billion, a buyout of Insmed could mark one of the biggest for the pharma industry since Pfizer’s mammoth $43 billion offer for Seagen back in 2023.
While holding off on commentary as to the report's validity, the team of Matt Phipps, Ph.D., at William Blair wrote Thursday that Sanofi is seen as a "rational fit" as a possible Insmed buyer, highlighting the respiratory overlap.
The biggest questions then, in the analysts' estimation, are whether Sanofi has capacity for the deal, and the price at which Insmed would be comfortable selling. It remains to be seen if Sanofi, with some 12 billion euros in current net debt, could "truly afford" an acquisition approaching $40 billion, Phipps' team said.
Still, investors have also speculated that Sanofi could add some Insmed assets to its joint venture with Regeneron to afford additional capital flexibility, if a deal truly is in the offing, the analysts pointed out.